Why Cutting Out a Keloid Alone Fails, and What Actually Changes the Odds

Ask most people with a keloid what they want, and the answer is simple: remove it. It sounds intuitive. The scar is a lump of excess tissue, so cut the lump off and the problem should be gone. Dermatologic surgeons hear this request constantly, and the honest answer they have to give is uncomfortable. Excision alone is one of the least reliable treatments in the entire keloid toolkit, with published recurrence rates ranging roughly from 45 percent to as high as 100 percent depending on the series, the body site, and how long patients were followed.

Understanding why requires letting go of the idea that a keloid is a foreign object sitting on the skin. A keloid is a behavior, not just a mass. It is the visible output of fibroblasts that have lost the normal off switch for wound healing. In ordinary repair, fibroblasts deposit collagen for a few weeks, then apoptosis and signaling changes wind the process down. In keloid-prone tissue, pathways driven by transforming growth factor beta, particularly the TGF-beta 1 isoform, stay switched on. Collagen production continues long after the wound has closed, and the scar grows beyond the original injury boundary, which is the defining feature separating keloids from hypertrophic scars.

Now consider what excision does. It removes the collagen mass, but it also creates a fresh, full thickness wound in skin that has already demonstrated it heals abnormally. The surgery is, in effect, a new injury delivered to the exact tissue most likely to overrespond to injury. Without something to interrupt the fibrotic signaling that follows, the recurrence is not bad luck. It is the expected biological outcome. Some recurrent keloids return larger than the original, because the surgical wound bed is bigger than the initial trigger, which may have been something as small as a pierced earlobe or an acne cyst.

This is why the modern standard is not excision versus no excision. It is excision plus what. Several adjuvants have meaningful evidence behind them.

Intralesional corticosteroids remain the workhorse. Triamcinolone acetonide injected into the wound margins at surgery and repeated at intervals afterward suppresses fibroblast proliferation, reduces collagen synthesis, and dampens the inflammatory signaling that feeds recurrence. Combined excision and steroid protocols bring recurrence down substantially compared with surgery alone, though results vary and steroids carry their own risks, including skin thinning, hypopigmentation, and visible telangiectasias when overused.

Superficial radiation therapy delivered within roughly 24 to 72 hours after excision is arguably the most effective adjuvant in the published literature, with many series reporting recurrence below 10 to 20 percent. The mechanism is direct: ionizing radiation targets the rapidly dividing fibroblasts and endothelial cells that would otherwise repopulate the wound and restart collagen overproduction. The timing matters because the goal is to hit those cells during their most active proliferative window. The trade-off is access, cost, and a small theoretical long term malignancy risk that most radiation oncologists consider very low at the doses used, but which still warrants a real conversation, especially for keloids on the chest near breast tissue or on the neck near the thyroid.

Pressure therapy deserves particular mention for earlobe keloids, one of the most common sites. Custom or commercial pressure earrings worn for several months after excision are believed to work through mechanotransduction and local hypoxia, reducing blood flow to the healing tissue and downregulating fibroblast activity. Compliance is the main obstacle, since meaningful benefit requires many hours of daily wear over a long period.

Intralesional 5-fluorouracil, an antimetabolite that blocks fibroblast proliferation, is often used alone or mixed with triamcinolone, and the combination appears to outperform steroid monotherapy in several comparative studies while causing less skin atrophy. Silicone sheeting and gels, while modest performers on established keloids, have reasonable evidence as postoperative maintenance, likely working through occlusion and hydration of the stratum corneum, which appears to quiet fibroblast signaling.

What should a patient take from all this? Three practical points. First, if a clinician offers excision with no adjuvant plan, ask why, because for true keloids that approach is hard to defend. Second, the follow-up schedule is part of the treatment, not an afterthought. Steroid injections, pressure devices, and monitoring typically extend six to twelve months after surgery, and skipping them undermines the whole effort. Third, recurrence risk is individual. Darker skin phototypes, a family history of keloids, high tension body sites like the chest and shoulders, and a history of prior recurrence all raise the stakes and may justify the more aggressive adjuvants.

The scalpel still has a role in keloid care, especially for large, pedunculated, or symptomatic lesions where injections alone cannot deliver acceptable results. But it works as one step in a protocol, never as the whole plan. The lump is the symptom. The healing behavior is the disease, and that is what the adjuvants exist to treat.